The Role of Adjuvant Therapy in Gastrointestinal Stromal Tumor after Operative Treatment
Authors: Ka-Ho Lok
Publication Date: 02 Oct 2009
Clinical Medicine: Gastroenterology 2009:2 25-27
Ka-Ho Lok
Division of Gastroenterology and Hepatology, Department of Medicine and Geriatrics, Tuen Mun Hospital, Hong Kong
Abstract
The treatment for localized advance gastrointestinal stromal tumor (GIST) is far from ideal. Up to 50% of patient developed post-operative recurrence and died within 5 years. Recently, imatinib was found to significantly improve recurrence-free survival in post-operative patients. The role of adjuvant therapy in high risk GIST patients is discussed.
Download this full text open access article
Send to Endnote
(412.86 KB PDF format)
Readers of this also read:
- The Role of Adjuvant Therapy in Gastrointestinal Stromal Tumor after Operative Treatment
- Modulation of the BRCA1 Protein and Induction of Apoptosis in Triple Negative Breast Cancer Cell Lines by the Polyphenolic Compound Curcumin
- The Metastasectomy and Timing of Pulmonary Metastases on the Outcome of Osteosarcoma Patients
- Unblocking Blockbusters: Using Boolean Text-Mining to Optimise Clinical Trial Design and Timeline for Novel Anticancer Drugs
- A Salt-Threshold Required for Exacerbating Insulin Resistance in Dahl Salt-Sensitive (S) Rats
